Ex-vivo 3D model for personalized medicine in breast cancer
2018
Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
Taselisib and ipatasertib are two inhibitors of the PI3K and AKT pathways, respectively, currently tested in clinical trials. Previous studies have shown that they have efficient anti-tumor activity when combined with anti-microtubule drugs in human breast cancer cell lines. Here, to better profile the treatment strategy with these inhibitors, a new ex-vivo 3D culture with human breast cancer samples is developed to identify new biomarkers that can predict treatment efficacy in individual patients. The results show that this model replicates in vitro the clinical features of the original tumors. Through next-generation sequencing, a correlation was found between mutations in PI3KA and the efficacy of the treatment. Moreover, several mutations in genes from other important signalling pathways were also found to induce resistance to the treatment, which would make them candidates as negative predictive factors. Overall, the researchers propose a new ex vivo 3D model that replicates human breast cancer features in vitro and allows to identify genetic markers of resistance and rapid drug screening for personalized medicine.
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs
Michele Orditura, Floriana Morgillo
Added on: 10-03-2021
[1] https://www.sciencedirect.com/science/article/abs/pii/S0960977618301450[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
